Become a Fan and "Like" us on FB

Saturday, September 27, 2014

WONDERFUL WORLD OF SCIENCE# STEM CELL TREATMENT



Regeneus to open HiQCell Regenerative Medicine Clinic in Singapore

Tuesday, September 23, 2014 by Proactive Investors

Regeneus Limited is set to open a HiQCell Regenerative Medicine Clinic at the prestigious Camden Medical Centre in Singapore, as the company launches its first offshore treatment centre.
Regeneus Limited is set to open a HiQCell Regenerative Medicine Clinic at the prestigious Camden Medical Centre in Singapore, as the company launches its first offshore treatment centre.
Regeneus Limited (ASX:RGS) is set to open a HiQCell Regenerative Medicine Clinic at the prestigious Camden Medical Centre in Singapore, as the company launches its first offshore treatment centre.

The clinic is to be led by Medical Director, Dr Patrick Goh, a leading sports and exercise medicine specialist.

This approval is notable given that HiQCell® will be used to treat high performance athletes in an environment with increased scrutiny and concern about performance enhancing substances.

The HiQCell treatment involves harvesting a small amount of a patient’s own stem cells from their adipose (fat) tissue.

The regenerative cells are then separated and concentrated before being re-injected in osteoarthritic-affected joints such as knees, hips and ankles.

It has undergone the highest level of clinical scrutiny – a double blind placebo-controlled safety trial.

Regeneus CEO, Professor Graham Vesey said, “This is a very exciting announcement for Regeneus as it reports against a major milestone and highlights the first location for treatment of HiQCell outside of
Australia.

"It makes good sense for Regeneus from a business perspective to select Singapore as the first international location for the delivery of our HiQCell treatment, as the regulatory environment is similar to what we’re used to in Australia and the standard of care is very high.”


Treatments in Singapore to commence late 2014

The HiQCell Regenerative Medicine Clinic will be located at the prestigious Camden Medical Centre in Singapore’s premier medical services district on Orchard Road where a new state of the art cell-processing laboratory has been established.

Singapore provides a natural first overseas market for HiQCell as it is recognised as a leading edge medical services hub for both local and international patient treatments.

Through the clinic, Dr Goh will provide patients in Singapore with access to Regeneus’ HiQCell, an innovative cell therapy for the treatment of osteoarthritis, with first treatments expected to commence in late 2014.

As well as assuming the role of Medical Director, at the HiQCell Regenerative Medicine Clinic, Dr Goh will become the initial treating medical practitioner for the HiQCell procedure.

Dr Goh is a leading sports medicine specialist who was chief medical officer for Team Singapore during the 2000 and 2004 Olympic Games.

He holds a number of positions within Singapore’s Ministry of Health, the Singapore Armed Forces and Defence Science Organisation (DSO) and the National Anti-Doping Advisory Board.

Dr Goh said, “HiQCell provides a viable treatment option for mid-stage, age or impact related osteoarthritis patients who might otherwise face ongoing debilitating pain, loss of function, inability to play sport and reduced quality of life.

"I am very pleased to be able to offer this treatment to my patients.”


How HiQCell works

The HiQCell treatment involves harvesting a small amount of a patient’s own stem cells from their adipose (fat) tissue and after separating and concentrating the regenerative cells these are re-injected in osteoarthritic-affected joints such as knees, hips and ankles.

The HiQCell treatment, which aims to reduce inflammation and repair damaged tissue is carried out under the supervision of the treating medical practitioner.

HiQCell has been used to treat more than 500 patients and over 1,000 arthritic joints.

The cell therapy procedure is supported by safety data from a randomised controlled clinical trial and long-term safety and efficacy data is tracked through Australia’s first Joint Registry for stem cell therapy.
 
Analysis
Today's news of expansion of HiQCell to Singapore follows solid progress in Australia.  Most recently, the Australian Football League granted a case-by-case approval for the use of its HiQCell® stem cell therapy.

Importantly, the AFL’s decision is not a general approval for stem cell therapies but only for HiQCell®.

No comments: